Anne-Marie Van Der Kevie-Kersemaekers

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2020 · 220 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Parental insertional balanced translocations are an important cause of apparently de novo CNVs in patients with developmental anomalies

Beata Nowakowska, Nicole de Leeuw, Claudia AL Ruivenkamp et al. · European Journal of Human Genetics · 2011 · 115 citations · Full text

Medicine, Genetics, Molecular Genetics +15

The importance of chromosome studies in Roberts syndrome/SC phocomelia and other cohesinopathies

Erica H. Gerkes, Anne-Marie Van Der Kevie-Kersemaekers, Mariam Yakin et al. · European Journal of Medical Genetics · 2009 · 87 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois et al. · The Lancet Oncology · 2022 · 58 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

The idiopathic preterm delivery methylation profile in umbilical cord blood DNA

Febilla Fernando, Remco Keijser, Peter Henneman et al. · BMC Genomics · 2015 · 48 citations · Full text

Medicine, Genetics, Molecular Biology +15